Tessera Therapeutics

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

3 November 2025 -- Massachusetts, US -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced three presentations of new preclinical data at the upcoming American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida, December 6 – 9, 2025.  “The data we’re presenting at...
101 South St, Somerville, MA 02143, United States

+1 857-356-4700